NPAT rose 17% but PBT only 7% as Finance segment profit fell

The dominant Finance segment delivered revenue of $16.7M (+23%) while its segment result slipped from $3.2M to $2.9M, a decline of about 11%. The Corporate and Other segment swung from a $2.1M positive result in the prior period to a $0.3M loss, while the small Research and Advisory unit moved from a loss to a modest profit.

Operating cash inflow of $4.2M comfortably exceeded NPAT, capex was negligible at $0.2M, and the cash balance lifted to $15.3M. Total assets grew to $163.3M and equity to $26.8M (NTA 6.65 cents per share). No dividend was declared.

PBT growth of around 7% is the cleaner read on the underlying business; the +17% NPAT figure benefits from a roughly six-percentage-point fall in the effective tax rate. Without that tax move, headline earnings growth would have been materially smaller, which matters for anyone treating the result as a clean indicator of operating momentum.

The core Finance segment compressed. Finance contributed 97% of revenue, but its segment result fell about 11% despite revenue growth of 23%. That gap points to margin pressure — funding cost, net interest margin, or impairment-related — in the part of the business that drives the group, and is the most important economic signal in the release.

The prior-year comparable was flattered by a Corporate item. A $2.1M positive contribution from Corporate and Other in FY23 became a $0.3M loss in FY24, a $2.4M unfavourable swing offset elsewhere. The headline +17% NPAT growth therefore rests on tax, a Research and Advisory turnaround, and a softer Finance result, rather than on a clean expansion of the lending franchise.

The release describes the year as a "record" outcome and references strong management of arrears, net interest margin and costs, but does not provide quantified NIM, arrears, or impairment disclosures in the materials reviewed.

The HY24 first half delivered 45.6% of full-year revenue and 45.7% of NPAT, so the year was modestly second-half weighted but not dramatically so. With balance-sheet growth (assets +20%, equity +10.5%) outpacing PBT growth, the read-through to FY25 depends heavily on whether Finance segment margins stabilise and whether the lower effective tax rate is repeatable rather than a one-year benefit.

ROE edged up to 9.8% from 9.3%, indicating earnings growth only modestly outpaced equity growth — capital was deployed faster than profit expansion.

However, the durability of the headline growth is more limited than the +17% NPAT print suggests. Three softening factors weaken the result quality: a lower effective tax rate accounts for a meaningful share of the NPAT uplift; the Corporate and Other contribution swung negatively by roughly $2.4M and was offset by a Research and Advisory turnaround that is small in absolute scale; and the dominant Finance segment's profit declined even as its revenue grew, which is the opposite of operating leverage. Stripping these out, the underlying lending franchise is running with revenue growth above profit growth, and the +25.3% top-line is a better indicator of business expansion than the +17% NPAT.

This briefing cannot assess net interest margin, arrears trends, funding cost composition, or capital adequacy headroom because those metrics are not disclosed in the supplied materials.